BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 38716601)

  • 1. [Clinical significance of IL-18 and IL-18-binding protein in bone marrow of patients with myelodysplastic syndrome].
    Wang T; Ran NY; Chen QL; Liu DL; Zang MT; Li NB; He X; Guan J; Fu R; Shao ZH
    Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):284-289. PubMed ID: 38716601
    [No Abstract]   [Full Text] [Related]  

  • 2. TIM3/CEACAM1 pathway involves in myeloid-derived suppressor cells induced CD8
    Yu S; Ren X; Meng F; Guo X; Tao J; Zhang W; Liu Z; Fu R; Li L
    Immunology; 2023 Feb; 168(2):273-289. PubMed ID: 35470423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Changes and clinical significance of CD8(+) T cell subset in patients with aplastic anemia, myelodysplastic syndrome and acute myeloid leukemia].
    Zhang JY; Xu HZ; Yin DM; Feng XM; Sui XH; Cui B; Ma CY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):203-8. PubMed ID: 23484720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXCL12+ stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes.
    Abe-Suzuki S; Kurata M; Abe S; Onishi I; Kirimura S; Nashimoto M; Murayama T; Hidaka M; Kitagawa M
    Lab Invest; 2014 Nov; 94(11):1212-23. PubMed ID: 25199050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Changes of natural kill cell in peripheral blood of patients with myelodysplastic syndrome].
    Mi H; Fu R; Wang H; Qu W; Ruan E; Wang X; Wang G; Liu H; Wu Y; Song J; Xing L; Guan J; Li L; Jiang H; Zhang W; Yue L; Shao Z
    Zhonghua Yi Xue Za Zhi; 2014 Mar; 94(10):737-41. PubMed ID: 24844955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Th17 Cells Exhibit Antitumor Effects in MDS Possibly through Augmenting Functions of CD8+ T Cells.
    Li J; Yue L; Wang H; Liu C; Liu H; Tao J; Qi W; Wang Y; Zhang W; Fu R; Shao Z
    J Immunol Res; 2016; 2016():9404705. PubMed ID: 27722177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
    Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
    Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-17 enhances the production of interferon-γ and tumour necrosis factor-α by bone marrow T lymphocytes from patients with lower risk myelodysplastic syndromes.
    Zhang Z; Li X; Guo J; Xu F; He Q; Zhao Y; Yang Y; Gu S; Zhang Y; Wu L; Chang C
    Eur J Haematol; 2013 May; 90(5):375-84. PubMed ID: 23331180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biology of the bone marrow microenvironment and myelodysplastic syndromes.
    Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM
    Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic significance of bone marrow levels of neurofibromatosis-1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Lu D; Nounou R; Beran M; Estey E; Manshouri T; Kantarjian H; Keating MJ; Albitar M
    Cancer; 2003 Jan; 97(2):441-9. PubMed ID: 12518368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [IL-32 mRNA Expression of Bone Marrow Stromal Cells and Its Correlation with Cell Apoptosis in Patients with Myelodysplastic Syndrome].
    Zhang YY; Xu L; Li DQ; Shao JH; Chen P; Zhao HY; Dong XB; Gu LP; Wu W
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Jun; 24(3):773-8. PubMed ID: 27342508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Abnormalities of CD34+ cells differentiation and bone marrow cell cycle in myelodysplastic syndrome].
    Li LJ; Fu R; Shao ZH; Wang HQ; Yue LZ; Ruan EB; Liu H; Wang J; Wang HL
    Zhonghua Nei Ke Za Zhi; 2010 Nov; 49(11):963-6. PubMed ID: 21211213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro deprivation of CD8(+)CD57(+)T cells promotes the malignant growth of bone marrow colony cells in patients with lower-risk myelodysplastic syndrome.
    Zheng Z; Qianqiao Z; Qi H; Feng X; Chunkang C; Xiao L
    Exp Hematol; 2010 Aug; 38(8):677-84. PubMed ID: 20394797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormal Macrophage Polarization in Patients with Myelodysplastic Syndrome.
    Zhang G; Yang L; Han Y; Niu H; Yan L; Shao Z; Xing L; Wang H
    Mediators Inflamm; 2021; 2021():9913382. PubMed ID: 34335093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [GDF11 level in patients with myelodysplastic syndrome and its clinical significance].
    Han Y; Wang H; Fu R; Qu W; Ruan E; Wang X; Wang G; Wu Y; Liu H; Song J; Guan J; Xing L; Li L; Jiang H; Liu H; Wang Y; Liu C; Zhang W; Shao Z
    Zhonghua Yi Xue Za Zhi; 2016 Mar; 96(8):620-4. PubMed ID: 26932855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors.
    Epling-Burnette PK; Bai F; Painter JS; Rollison DE; Salih HR; Krusch M; Zou J; Ku E; Zhong B; Boulware D; Moscinski L; Wei S; Djeu JY; List AF
    Blood; 2007 Jun; 109(11):4816-24. PubMed ID: 17341666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [TET2 and DLK1 gene expression and their clinical significance in bone marrow CD(3)(+) T cells of patients with myelodysplastic syndrome].
    Zhang W; Fu R; Wang HQ; Li LJ; Yue LZ; Liu H; Qu W; Liang Y; Wang GJ; Wang XM; Wu YH; Liu H; Song J; Guan J; Xing LM; Shao ZH
    Zhonghua Nei Ke Za Zhi; 2012 Jul; 51(7):543-6. PubMed ID: 22943828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural Killer Cell Subpopulations and Inhibitory Receptor Dynamics in Myelodysplastic Syndromes and Acute Myeloid Leukemia.
    Cianga VA; Campos Catafal L; Cianga P; Pavel Tanasa M; Cherry M; Collet P; Tavernier E; Guyotat D; Rusu C; Aanei CM
    Front Immunol; 2021; 12():665541. PubMed ID: 33986753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy.
    Radujkovic A; Dietrich S; Andrulis M; Benner A; Longerich T; Pellagatti A; Nanda K; Giese T; Germing U; Baldus S; Boultwood J; Ho AD; Dreger P; Luft T
    Int J Cancer; 2016 Sep; 139(6):1402-13. PubMed ID: 27170453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-2 therapy for myelodysplastic syndrome: does it work?
    Ogata K; Yokose N; Nomura T
    Leuk Lymphoma; 1995 May; 17(5-6):411-5. PubMed ID: 7549831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.